Related references
Note: Only part of the references are listed.Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Immunomodulatory drugs Revlimid (R) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
The role of angiogenesis inhibitors in prostate cancer
Jeanny B. Aragon-Ching et al.
CANCER JOURNAL (2008)
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
William L. Dahut et al.
CLINICAL CANCER RESEARCH (2008)
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
Giuseppe Di Lorenzo et al.
EUROPEAN UROLOGY (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
K. N. Chi et al.
ANNALS OF ONCOLOGY (2008)
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S. Steinbild et al.
BRITISH JOURNAL OF CANCER (2007)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E. DePrimo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer
DJ George et al.
UROLOGY (2004)
In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: Induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor
RP Singh et al.
CLINICAL CANCER RESEARCH (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics
Y Takei et al.
CANCER RESEARCH (2004)
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy
SF Shariat et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer
M Kohli et al.
UROLOGY (2003)
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases
H Uehara et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF
RH Cao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Leptin is associated with increased prostate cancer risk:: A nested case-referent study
P Stattin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Share Paper
